Aptose Biosciences (TSE:APS) has released an update.
Aptose Biosciences has announced positive results for tuspetinib, highlighting its safety and effectiveness across multiple mutational subtypes in AML, leading to a new triplet therapy pilot study. The company also reported successful public and private funding rounds in early 2024, raising a combined total of approximately $13.7 million to support their ongoing clinical trials and development programs.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.
